期刊發表

類別
日期
新藥研發
2021-05
InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19
作者 Jonathan Fang, He-Ru Chen, Yunlong Tseng, Wan-Ni Yu, Tzung-Ju Wu, Yi-Chen Tsai, Tien-Tzu Tai, Sheue-Fang Shih, Keelung Hong; InspirMed, Inc., TLC Biopharmaceuticals Inc., Taiwan Liposome Company (TLC), Ltd.
已發表
新藥研發
2021-03
Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy
作者 Kevin Chih-Yang Huang, Shu-Fen Chiang, Pei-Chen Yang, Tao-Wei Ke, Tsung-Wei Chen, Ching-Han Hu, Yi-Wen Huang, Hsin-Yu Chang, William Tzu-Liang, and K. S. Clifford Chao
已發表
新藥研發
2020-07
A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study
作者 Tien-Tzu Tai, Tzung-Ju Wu, Yi-Chen Tsai, Hui-Ting Wang, An-Min Wang and Sheue-Fang Shih; Taiwan Liposome Company (TLC), Ltd., Taipei, Taiwan
已發表
新藥研發
2020-05
Single Intra-articular injection of TLC599 in Patients with Osteoarthritis Knee Pain: Subgroup Analyses of a Placebo-controlled 24-week Phase 2 Trial
作者
已發表
新藥研發
2019-10
Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
作者 Sheue-Fang Shih, Carl Brown, Tien-Tzu Tai and Wing Chuang; Taiwan Liposome Company (TLC), Ltd., Taipei, Taiwan
已發表
新藥研發
2019-10
A Phase 1/2, Randomized, Double-blind, Comparator-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TLC590 for Postsurgical Pain Management following Inguinal Hernia Repair
作者 Todd M. Bertoch, Carl O. Brown, Chih-Feng Wu, Pei-Hsien Hu, Tien-Tzu Tai, Weenee Y. N. Jao, Cheng-Yu Kuo, Hui-Ting Wang, Min-Wen, Kuo, Yun-Long Tseng, JBR Clinical Research, Salt Lake City, UT, USA and Taiwan Liposome Company (TLC), Taipei City, Taiwan
已發表
新藥研發
2019-10
Formulation and Evaluation of Multilamellar Vesicles Ropivacaine in Pain Management
作者 Hao-Wen Kao, Yi-Yu Lin, Walter J Gwathney, Keelung Hong, TLC Biopharmaceuticals, Inc., South San Francisco, CA 94080, USA; Taiwan Liposome Company, Ltd., Taipei 11503, Taiwan
已發表
新藥研發
2019-09
In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mouse Models
作者 Wan-Ni. Yu, Jo-Hsin Tang, Tzung-Ju Wu, Yi-Chen Tsai and Hui-Ting Wang; Non-clinical Department, Pharmacokinetic Department, Taiwan Liposome Company, Taipei City, Taiwan
已發表
新藥研發
2019-06
Pharmacokinetic and Toxicokinetic Studies of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) Following Intra-articular Injection in Dogs
作者 Tzung-Ju Wu, Wan-Ni. Yu, Ming-Ju Wu, Po-Chun Chang, Hui-Ting Wang and Sheue-Fang Shih; Taiwan Liposome Company, Taipei, Taiwan
已發表 歐洲抗風濕病聯盟（EULAR）歐洲科學大會
新藥研發
2019-05
Single Intra-articular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
作者 D. Hunter, C-C. Chang, J-C. Wei, H-Y. Lin, C. Brown, S-F. Shih; Univ. of Sydney, Sydney, Australia, Royal North Shore Hosp., Sydney, Australia, Div. of Allergy, Immunology and Rheumatology, Dept. of Internal Med., Sch. of Med., Coll. of Med., Taipei Med. Univ., Taipei, Taiwan, Div. of Allergy, Immunology and
Rheumatology, Chung Shan Med. Univ. Hosp., Taipei, Taiwan, Dept. of Internal Med., Cheng Hsin Gen. Hosp., Taipei,
Taiwan, Dept. of Allergy, Immunology and Rheumatology, Taipei Veterans Gen. Hosp., Taipei, Taiwan, Taiwan
Liposome Company, Taipei, Taiwan
已發表 2019國際關節炎研討大會(Osteoarthritis Research Society International World Congress, OARSI)
of
3
您即將離開TLC網站

您將前往外部網站，該網站之內容及其維護等將由第三方對其負全部責任。

TLC僅提供此連結予您參考， TLC不對任何第三方網站之隱私政策負責。我們提醒您詳讀您造訪之各網站的隱私政策。

點擊"停留"或右上角關閉視窗以留在此網站，或點擊"繼續"

繼續 停留